| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| ViroPharma Inc has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 27-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (VPHM). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (VPHM). | 5 |
$18 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| VPHM: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | VIROPHARMA INCORPORATED (VPHM=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of VIROPHARMA INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for VPHM | 13 |
$25 |
| 23-Nov-2009 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 22-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) | 103 |
$169 |
| 22-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) | 101 |
$169 |
1.48% Nasdaq 
Research Reports
